A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

Part of paid clinical trials in Gainesville, Florida.

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study ID
NCT07759154
Phase
PHASE3
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Centanafadine XR — DRUG
    Oral capsules

Study Details

The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).

Key Dates

First listed
Aug 12, 2026
Start date
Sep 1, 2026
Status verified
Sep 2026
Primary completion
May 27, 2027
Completion
May 27, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Centanafadine XR
    Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks.

Primary Outcome Measure

Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score [ Time Frame: Baseline up to Week 8 ]

Central Contacts

Locations (16)

FacilityCityStateZIPSite coordinators
Sarkis Clinical Trials - GainesvilleGainesvilleFlorida32607
Otsuka Call Center
844-687-8522
Sarkis (PRINCIPAL_INVESTIGATOR)
CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)JacksonvilleFlorida32256
Otsuka Call Center
844-687-8522
Jones (PRINCIPAL_INVESTIGATOR)
Accel Research Sites-MaitlandMaitlandFlorida32751
Otsuka Call Center
844-687-8522
Marraffino (PRINCIPAL_INVESTIGATOR)
Nola Research WorksNew OrleansLouisiana70125
Otsuka Call Center
844-687-8522
Hebert (PRINCIPAL_INVESTIGATOR)
Boston Clinical TrialsBostonMassachusetts02132
Otsuka Call Center
844-687-8522
Mezhebovsky (PRINCIPAL_INVESTIGATOR)
Adams Clinical - WatertownWatertownMassachusetts02472
Otsuka Call Center
844-687-8522
Rutrick (PRINCIPAL_INVESTIGATOR)
St. Charles Psychiatric Associates/Midwest Research GroupSaint CharlesMissouri63304
Otsuka Call Center
844-687-8522
Mattingly (PRINCIPAL_INVESTIGATOR)
Center for Psychiatry and Behavioral Medicine. Inc.Las VegasNevada89128
Otsuka Call Center
844-687-8522
Childress (PRINCIPAL_INVESTIGATOR)
Center for Emotional FitnessCherry HillNew Jersey08002
Otsuka Call Center
844-687-8522
Corcoran (PRINCIPAL_INVESTIGATOR)
The Medical Research Network, LLCNew YorkNew York10128
Otsuka Call Center
844-687-8522
Careri (PRINCIPAL_INVESTIGATOR)
Patient Priority Clinical TrialsCincinnatiOhio45215
Otsuka Call Center
844-687-8522
Popovitz (PRINCIPAL_INVESTIGATOR)
Summit Research NetworkPortlandOregon97210
Otsuka Call Center
844-687-8522
Essink (PRINCIPAL_INVESTIGATOR)
Donald J. Garcia, Jr, MD, PAAustinTexas78737
Otsuka Call Center
844-687-8522
Garcia (PRINCIPAL_INVESTIGATOR)
Houston Clinical Trials LLCBellaireTexas77401
Otsuka Call Center
844-687-8522
Katic (PRINCIPAL_INVESTIGATOR)
Kaleidoscope Clinical ResearchHoustonTexas77089
Otsuka Call Center
844-687-8522
Higgins (PRINCIPAL_INVESTIGATOR)
Core Clinical ResearchEverettWashington98201
Otsuka Call Center
844-687-8522
Knutson (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gainesville, FL

By condition

Related Studies